Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon System

Documenti analoghi

• In Vitro and In Vivo Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450
  di: Pilot-Matias, Tami, et al.
  Pubblicazione: (2015)
• VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells
  di: Lin, Kai, et al.
  Pubblicazione: (2006)
• Selection of Resistance in Protease Inhibitor-Experienced, Human Immunodeficiency Virus Type 1-Infected Subjects Failing Lopinavir- and Ritonavir-Based Therapy: Mutation Patterns and Baseline Correlates
  di: Mo, Hongmei, et al.
  Pubblicazione: (2005)
• The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons
  di: Lahser, Frederick C., et al.
  Pubblicazione: (2016)
• Restoration of the Activated Rig-I Pathway in Hepatitis C Virus (HCV) Replicon Cells by HCV Protease, Polymerase, and NS5A Inhibitors In Vitro at Clinically Relevant Concentrations
  di: Kalkeri, Gururaj, et al.
  Pubblicazione: (2013)